Europe Prostate Cancer Biomarkers Market Size & Outlook
Related Markets
Europe prostate cancer biomarkers market highlights
- The Europe prostate cancer biomarkers market generated a revenue of USD 1,323.8 million in 2024.
- The market is expected to grow at a CAGR of 13.3% from 2025 to 2033.
- In terms of segment, protein biomarkers was the largest revenue generating type in 2024.
- Metabolomic Biomarkers is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2033.
Europe data book summary
| Market revenue in 2024 | USD 1,323.8 million |
| Market revenue in 2033 | USD 4,052.7 million |
| Growth rate | 13.3% (CAGR from 2025 to 2033) |
| Largest segment | Protein biomarkers |
| Fastest growing segment | Metabolomic Biomarkers |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Genetic Biomarkers, Protein Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers |
| Key market players worldwide | Exact Sciences Corp, Myriad Genetics Inc, Bio-Techne Corp, OPKO Health Inc, MDxHealth SA, Veracyte Inc, Beckman Coulter, Nucleix, DiaCarta |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.3% of the global prostate cancer biomarkers market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,065.6 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Prostate Cancer Biomarkers Market Scope
Prostate Cancer Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| DiaCarta | View profile | 11-50 | Hayward, California, United States, North America | http://diacarta.com |
| Nucleix | View profile | 11-50 | Rehovot, HaMerkaz, Israel, Asia | http://nucleix.com |
| MDxHealth SA | View profile | - | - | - |
| Veracyte Inc | View profile | - | - | - |
| Beckman Coulter | View profile | 10001+ | Brea, California, United States, North America | http://www.beckmancoulter.com |
| OPKO Health Inc | View profile | 3930 | 4400 Biscayne Boulevard, Miami, FL, United States, 33137 | https://www.opko.com |
| Bio-Techne Corp | View profile | 3050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | https://www.bio-techne.com |
| Exact Sciences Corp | View profile | 6600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | https://www.exactsciences.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
Europe prostate cancer biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer biomarkers market will help companies and investors design strategic landscapes.
Protein biomarkers was the largest segment with a revenue share of 64.9% in 2024. Horizon Databook has segmented the Europe prostate cancer biomarkers market based on genetic biomarkers, protein biomarkers, cell-based biomarkers, metabolomic biomarkers covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Europe prostate cancer biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe prostate cancer biomarkers market databook
-
Our clientele includes a mix of prostate cancer biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe prostate cancer biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Europe prostate cancer biomarkers market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Europe prostate cancer biomarkers market size, by country, 2021-2033 (US$M)
Europe Prostate Cancer Biomarkers Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
